Skip to main content

ceftolozane/tazobactam (Zerbaxa®)

 

Following non-submission

AWMSG advice

Status: Not endorsed (Statement of Advice)

In the absence of a submission from the holder of the marketing authorisation, ceftolozane/tazobactam (Zerbaxa®) cannot be endorsed for use within NHS Wales for the treatment of hospital-acquired pneumonia, including ventilator‑associated pneumonia in adults. Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines.

 Statement of Advice (SOA): ceftolozane/tazobactam (Zerbaxa) 2182 (PDF, 120Kb)

Medicine details

Medicine name ceftolozane/tazobactam (Zerbaxa®)
Formulation 1 g/0.5 g powder for concentrate for solution for infusion
Reference number 2182
Indication

For the treatment of hospital-acquired pneumonia, including ventilator‑associated pneumonia in adults

Company Merck Sharp & Dohme Ltd
BNF chapter Infections
Submission type Non-submission
Status Not endorsed (Statement of Advice)
Date of issue 18/02/2020
Further information

AWMSG position statement on the appraisal of antimicrobial medicines

Follow AWTTC: